Skip to content

D&A at other companies

Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$162.1M+7.4%
Medtronic logo
MedtronicMDT
$716M-14.8%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$30.5M+4.1%
Enovis logo
EnovisENOV
$41.9M+0.2%
Globus Medical logo
Globus MedicalGMED
$29.53M-55.3%
Solventum logo
SolventumSOLV

Other financials

Income statement

See full
Revenue$317.0M-1.3%
Gross profit$183.4M+3.2%
Operating income$25.4M+59.3%
Net income$13.8M+129%
EPS (diluted)$0.45+137%

Balance sheet

See full
Cash & equivalents$35.0M-1.3%
Total debt$862.6M-3.6%
Total equity$1.0B+4.1%
Total assets$2.3B+0.8%

Cash flow

See full
Operating cash flow$13.5M-67.6%
CapEx$2.9M-23.5%
Free cash flow$10.6M-72.0%

Valuation

See full
Market cap$1.07B-34.0%
Enterprise value$1.89B-23.5%
P/E19.4×+5.8×
P/S0.8×-0.5×

Profitability

See full
Gross margin55.2%-1.0pp
Operating margin8.2%-5.6pp
Net margin4%-5.0pp
FCF margin9%-3.5pp

Returns & leverage

See full
Return on equity5.5%-7.5pp
Debt / equity0.8×-0.1×
Current ratio2.3×0.0×

Where this comes from

Reported directly by CONMED in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: CONMED’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about CONMED's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CONMED's D&A?
CONMED (CNMD) reported D&A of $8.7M in Q1 2026.
How has CONMED's D&A changed year-over-year?
CONMED's D&A decreased by 0.0% year-over-year, from $8.7M to $8.7M.
What is the long-term trend for CONMED's D&A?
Over 4 years (2021 to 2025), CONMED's D&A has grown at a 1.5% compound annual growth rate (CAGR), from $33.2M to $35.2M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.